The Mediclinic International Board proposes a final dividend from retained earnings of 3.00 pence per ordinary share for the year ended 31 March 2022 for approval by the Company's shareholders at the annual general meeting on Thursday, 28 July 2022.
Other financial highlights include:
●Group revenue up 8%, driven by increase in client activity; revenue up 5% on pre-pandemic levels
●Material improvement in Group adjusted EBITDA margin to 16.1% (FY21: 14.2%; FY20: 17.5%)
●Group adjusted earnings per share ('EPS') increased 65% to 22.6p (FY21: 13.7p; FY20: 24.0p)
●Reduced the leverage ratio to 3.9x (FY21: 5.1x), below pre-pandemic levels (FY20: 4.3x)
●Proposed dividend re-instatement at 3.00 pence per share (FY21: nil)
